CARSGEN-B (02171) announced that, based on a preliminary assessment of the Group's latest unaudited management accounts for the year ending December 31, 2025 (the reporting period), and information currently available to the Board, the Group expects to report a decrease in both net loss and adjusted net loss year-on-year. This projection is attributed to a combination of factors, including the commercialization of Zevor-cel (泽沃基奥仑赛注射液) and the acceptance of the New Drug Application (NDA) for sepr-cel (舒瑞基奥仑赛注射液) by the National Medical Products Administration (NMPA). The details are as follows: (a) for the reporting period, the net loss is expected to be no more than approximately RMB 120 million, compared to approximately RMB 798 million for the year ended December 31, 2024; and (b) for the reporting period, the adjusted net loss (which refers to net loss excluding share-based compensation, a non-IFRS measure) is expected to be no more than approximately RMB 95 million, compared to approximately RMB 789 million for the year ended December 31, 2024.

The reduction in losses is primarily due to the combined effect of the following factors: (i) increased commercialization revenue from Zevor-cel in Mainland China; (ii) the impact of foreign exchange fluctuations; and (iii) a significant decrease in research and development expenses for Zevor-cel and sepr-cel.